amin firoozmand, MD, U.S. board-certified hematologist and medical oncologist with additional subspecialty training in bone marrow transplantation

I am a U.S. board-certified hematologist and medical oncologist with additional subspecialty training in bone marrow transplantation. My medical education began at the National Organization for Development of Exceptional Talents (NODET) and Isfahan University of Medical Sciences (IUMS) in Iran.
I completed a postdoctoral research fellowship in stem cell biology and oncology at Johns Hopkins Hospital, where I had the privilege of working with Nobel Laureate Dr. Gregg Semenza on a project involving bone marrow-derived angiogenic stem cells.
During my internal medicine residency at University of Maryland-affiliated hospitals, I developed a strong foundation in oncology through diverse clinical rotations. Following residency, I served as an Assistant Professor of Medicine and academic hematology-oncology hospitalist at the Seidman Comprehensive Cancer Center in Cleveland. In this role, I was actively involved in medical education, mentoring residents and students, and participating in the residency admissions process.
I went on to complete fellowships in hematology and oncology at the University of Minnesota, and in stem cell transplantation at Cleveland Medical Center. My research in these fields has led to multiple publications and presentations at national scientific meetings.
Currently, I practice at the Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital in San Antonio, Texas. My clinical and research interests focus on advanced stem cell and cellular therapies for hematologic malignancies, with a special emphasis on multiple myeloma.
I am an active member of several professional organizations, including the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the American Society for Transplantation and Cellular Therapy (ASTCT).
Financial relationships
-
Type of financial relationship:There are no financial relationships to disclose.Date added:05/28/2025Date updated:05/28/2025